Real-world treatment patterns, healthcare resource utilization and total cost of care in mantle cell lymphoma from US commercial claims

References

• Zhou Y, Wang H, Fang W et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 113(4), 791–798 (2008).
   PubMed Web of Science ®Google Scholar
• Leux C, Maynadié M, Troussard X et al. Mantle cell lymphoma epidemiology: a population-based study in France. Ann. Hematol. 93(8), 1327–1333 (2014).
   PubMed Web of Science ®Google Scholar
• Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin. Cancer Biol. 21(5), 293–298 (2011).
   PubMed Web of Science ®Google Scholar
• Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 92(8), 806–813 (2017).
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Hess G, Atta J et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann. Hematol. 91(11), 1765–1772 (2012).
   PubMed Web of Science ®Google Scholar
• Di M, Cui C, Kothari SK et al. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Adv. 6(11), 3339–3342 (2022).
   PubMed Web of Science ®Google Scholar
• Martin P, Cohen JB, Wang M et al. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J. Clin. Oncol. 41(3), 541–554 (2023).
   PubMed Web of Science ®Google Scholar
• Dreyling M, Campo E, Hermine O et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv62–iv71 (2017).
   PubMedGoogle Scholar
• Mckay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br. J. Haematol. 182(1), 46–62 (2018).
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Scott DW, Slack GW et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann. Oncol. 28(10), 2489–2495 (2017).
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J. Clin. Oncol. 27(8), 1209–1213 (2009).
   PubMed Web of Science ®Google Scholar
• Lymphoma Research Foundation. Mantle cell lymphoma: FDA updates. https://lymphoma.org/aboutlymphoma/nhl/mcl/mclfdaupdates/ (January 6, 2022).
   Google Scholar
• Wang M, Munoz J, Goy A et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382(14), 1331–1342 (2020).
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J. Clin. Oncol. 41(3), 555–567 (2023).
   PubMed Web of Science ®Google Scholar
• Wang M, Siddiqi T, Gordon LI et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J. Clin. Oncol. 42(10), 1146–1157 (2024).
   PubMed Web of Science ®Google Scholar
• Buege MJ, Kumar A, Dixon BN et al. Management of mantle cell lymphoma in the era of novel oral agents. Ann. Pharmacother. 54(9), 879–898 (2020).
   PubMed Web of Science ®Google Scholar
• Schieber M, Gordon LI, Karmali R. Current overview and treatment of mantle cell lymphoma. F1000Res. 7(F1000 Faculty Rev), 1136 (2018).
   Google Scholar
• Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J. Hematol. Oncol. 13(1), 79 (2020).
   PubMed Web of Science ®Google Scholar
• Rajguru S, Kahl BS. Emerging therapy for the treatment of mantle cell lymphoma. J. Natl Compr. Canc. Netw. 12(9), 1311–1318; quiz 1318 (2014).
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Albertsson-Lindblad A, Brown PN et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 124(8), 1288–1295 (2014).
   PubMed Web of Science ®Google Scholar
• Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk. Lymphoma 60(4), 955–963 (2019).
   PubMed Web of Science ®Google Scholar
• Kabadi SM, Near A, Wada K, Burudpakdee C. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med. 8(17), 7174–7185 (2019).
   PubMed Web of Science ®Google Scholar
• Watson Health. IBM MarketScan Research Databases User Guide Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database, Data Year 2019 Edition.
   Google Scholar
• Watson Health. IBM MarketScan Research Databases for life sciences researchers. https://www.ibm.com/downloads/cas/OWZWJ0QO (December 5, 2022).
   Google Scholar
• Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373–383 (1987).
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 42(6), 613–619 (1992).
   Google Scholar
• D'souza A, Fretham C, Lee SJ et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol. Blood Marrow Transplant. 26(8), e177–e182 (2020).
   PubMed Web of Science ®Google Scholar
• Garg M, Satija A, Song Y et al. Economic burden and treatment patterns among patients with mantle cell lymphoma in the US: a retrospective claims analysis. Blood 140(Suppl. 1), 7920–7921 (2022).
   Google Scholar
• Narkhede M, Goyal G, Shea L, Mehta A, Giri S. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 6(14), 4122–4131 (2022).
   PubMed Web of Science ®Google Scholar